MA32322B1 - Dérivés d'urée macrocyclique et de sulfamide en tant qu'inhibiteurs de tafia - Google Patents

Dérivés d'urée macrocyclique et de sulfamide en tant qu'inhibiteurs de tafia

Info

Publication number
MA32322B1
MA32322B1 MA33377A MA33377A MA32322B1 MA 32322 B1 MA32322 B1 MA 32322B1 MA 33377 A MA33377 A MA 33377A MA 33377 A MA33377 A MA 33377A MA 32322 B1 MA32322 B1 MA 32322B1
Authority
MA
Morocco
Prior art keywords
tafia inhibitors
sulphonamide derivatives
macrocyclic urea
inhibitors
macrocyclic
Prior art date
Application number
MA33377A
Other languages
Arabic (ar)
English (en)
Inventor
Christopher Kallus
Mark Broenstrup
Andreas Evers
Anja Globisch
Herman Schreuder
Michael Wagner
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA32322B1 publication Critical patent/MA32322B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/01—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne des composés de la formule (i) qui sont des inhibiteurs de thrombine activée-fibrinolyse activable. Les composés de la formule i sont appropriés pour la fabrication de médicaments pour la prophylaxie, la prévention secondaire et la thérapie d'une ou plusieurs maladies qui s'accompagnent de thromboses, d'embolies, d'hypercoagulabilité ou de modifications fibrotiques.
MA33377A 2008-06-06 2010-11-30 Dérivés d'urée macrocyclique et de sulfamide en tant qu'inhibiteurs de tafia MA32322B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290520 2008-06-06
PCT/EP2009/003650 WO2009146802A1 (fr) 2008-06-06 2009-05-22 Dérivés macrocycliques d’urée et de sulfamide comme inhibiteurs de tafia

Publications (1)

Publication Number Publication Date
MA32322B1 true MA32322B1 (fr) 2011-05-02

Family

ID=39800716

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33377A MA32322B1 (fr) 2008-06-06 2010-11-30 Dérivés d'urée macrocyclique et de sulfamide en tant qu'inhibiteurs de tafia

Country Status (35)

Country Link
US (5) US8580777B2 (fr)
EP (1) EP2300462B1 (fr)
JP (1) JP5531011B2 (fr)
KR (1) KR101673886B1 (fr)
CN (1) CN102056922B (fr)
AR (1) AR072007A1 (fr)
AU (1) AU2009254257B2 (fr)
BR (1) BRPI0913349A2 (fr)
CA (1) CA2726554C (fr)
CL (1) CL2009001358A1 (fr)
CO (1) CO6321271A2 (fr)
CR (1) CR11807A (fr)
CY (1) CY1115604T1 (fr)
DK (1) DK2300462T3 (fr)
DO (1) DOP2010000363A (fr)
EC (1) ECSP10010655A (fr)
ES (1) ES2494390T3 (fr)
HK (1) HK1152936A1 (fr)
HN (1) HN2010002558A (fr)
HR (1) HRP20140787T1 (fr)
IL (1) IL209772A (fr)
MA (1) MA32322B1 (fr)
MX (1) MX2010012793A (fr)
NI (1) NI201000203A (fr)
NZ (1) NZ589671A (fr)
PL (1) PL2300462T3 (fr)
PT (1) PT2300462E (fr)
RU (1) RU2502736C2 (fr)
SI (1) SI2300462T1 (fr)
SV (1) SV2010003747A (fr)
TW (1) TWI455928B (fr)
UA (1) UA104002C2 (fr)
UY (1) UY31868A (fr)
WO (1) WO2009146802A1 (fr)
ZA (1) ZA201007719B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102056922B (zh) 2008-06-06 2013-11-20 赛诺菲-安万特 作为tafia抑制剂的大环脲和磺酰胺衍生物
EP2321301A4 (fr) 2008-06-23 2011-09-28 Astrazeneca Ab Nouveaux carboxamides hétérocycliques utilisés comme inhibiteurs de thrombine
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
HUE034118T2 (en) * 2012-03-06 2018-01-29 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
WO2014198620A1 (fr) * 2013-06-10 2014-12-18 Sanofi Dérivés d'urée macrocycliques utiles en tant qu'inhibiteurs de tafia, leur preparation et leur utilisation en tant que produits pharmaceutiques
UY35809A (es) * 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
CN103755852B (zh) * 2013-12-18 2015-12-09 湖北大学 线型聚苯乙烯支载(4s)-(4’-氧苄基)-2-正丁基环磺酰胺及其制备方法和用途
CN106631832A (zh) * 2016-10-08 2017-05-10 帕潘纳(北京)科技有限公司 一种氨基醚类化合物的制备方法
US10411291B2 (en) * 2017-03-22 2019-09-10 Nanotek Instruments, Inc. Multivalent metal ion battery having a cathode layer of protected graphitic carbon and manufacturing method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU667995B2 (en) 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
US5888971A (en) * 1996-02-20 1999-03-30 Ortho Pharmaceutical Corporation, Inc. Macrocyclic peptides useful in the treatment of thrombin related disorders
DE69824433D1 (en) 1997-08-28 2004-07-15 Biovitrum Ab Proteintyrosinphosphatase inhibitoren
US6124278A (en) * 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
US6482921B1 (en) 1999-01-28 2002-11-19 Essential Therapeutics, Inc. Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use
EP1130022B1 (fr) * 2000-02-29 2009-07-22 Universita Degli Studi di Firenze 3-Aza-6,8-dioxabicyclo[3.2.1]octanes et d'analogues et bibliothèques combinatoires les contenant
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla
KR20090087044A (ko) 2006-12-06 2009-08-14 사노피-아벤티스 ＴＡＦＩａ 억제제로서의 요소 및 설파미드 유도체
CN102056922B (zh) 2008-06-06 2013-11-20 赛诺菲-安万特 作为tafia抑制剂的大环脲和磺酰胺衍生物

Also Published As

Publication number Publication date
CL2009001358A1 (es) 2009-11-27
AU2009254257B2 (en) 2013-11-21
EP2300462A1 (fr) 2011-03-30
UA104002C2 (ru) 2013-12-25
CR11807A (es) 2011-02-16
DOP2010000363A (es) 2010-12-15
US9126955B2 (en) 2015-09-08
NZ589671A (en) 2012-03-30
WO2009146802A1 (fr) 2009-12-10
CY1115604T1 (el) 2017-01-04
SI2300462T1 (sl) 2014-09-30
IL209772A0 (en) 2011-02-28
DK2300462T3 (da) 2014-08-18
US20110178130A1 (en) 2011-07-21
CA2726554C (fr) 2015-02-24
US8722655B2 (en) 2014-05-13
KR101673886B1 (ko) 2016-11-08
US20140206760A1 (en) 2014-07-24
MX2010012793A (es) 2010-12-14
CN102056922B (zh) 2013-11-20
NI201000203A (es) 2011-09-29
IL209772A (en) 2016-04-21
JP2011521981A (ja) 2011-07-28
UY31868A (es) 2010-01-05
KR20110020795A (ko) 2011-03-03
HRP20140787T1 (hr) 2014-11-21
RU2502736C2 (ru) 2013-12-27
US20160024033A1 (en) 2016-01-28
SV2010003747A (es) 2011-03-15
PT2300462E (pt) 2014-08-05
AU2009254257A1 (en) 2009-12-10
PL2300462T3 (pl) 2014-10-31
ECSP10010655A (es) 2011-01-31
AR072007A1 (es) 2010-07-28
CO6321271A2 (es) 2011-09-20
ZA201007719B (en) 2011-07-27
US20140039011A1 (en) 2014-02-06
TWI455928B (zh) 2014-10-11
CN102056922A (zh) 2011-05-11
ES2494390T3 (es) 2014-09-15
US9309207B2 (en) 2016-04-12
BRPI0913349A2 (pt) 2015-11-24
CA2726554A1 (fr) 2009-12-10
US8580777B2 (en) 2013-11-12
US9688645B2 (en) 2017-06-27
TW201008917A (en) 2010-03-01
EP2300462B1 (fr) 2014-05-21
HK1152936A1 (en) 2012-03-16
RU2010154089A (ru) 2012-07-20
US20160251324A1 (en) 2016-09-01
HN2010002558A (es) 2012-08-28
JP5531011B2 (ja) 2014-06-25

Similar Documents

Publication Publication Date Title
MA32322B1 (fr) Dérivés d'urée macrocyclique et de sulfamide en tant qu'inhibiteurs de tafia
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
CR20110077A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
NO20090202L (no) Prolylhydroksylaseinhibitorer
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
EA201290267A1 (ru) Производные диоксабицикло[3.2.1]октан-2,3,4-триола
BRPI0510159A (pt) derivados de imidazol como inibidores de tafia
WO2007150015A3 (fr) Procédé de traitement
EA201200174A1 (ru) Производные оксазина и их применение в качестве ингибиторов bace для лечения неврологических нарушений
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
DOP2009000141A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteína quinasa
UA107115C2 (uk) Тіоацетатні похідіні піридину, композиція на їх основі та їх застосування
ATE530524T1 (de) Substituierte sulfonamid-derivate
WO2009026166A3 (fr) Composés de flavonol anti-infectieux et leurs procédés d'utilisation
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
TW200738651A (en) Cyclohexyl sulfonamide derivatives
CL2009001349A1 (es) Compuestos derivados de urea sustituidos con 1,4-dihidroquinolin-4-ona, inhibidores de adn girasa bacteriana y/o topoisomerasa iv bacteriana; composicion farmceutica; util para el tratamiento de una infeccion bacteriana.
EA201170828A1 (ru) Конденсированные гетероциклические производные оксадиазола, подходящие для лечения рассеянного склероза
CY1116840T1 (el) Χρηση 24-norudca
MX2009005516A (es) Derivados de urea y de sulfamida en calidad de inhibidores de tafia.
MY150745A (en) Isoserine derivatives for use as coagulation factor ixa inhibitors
MX2011013869A (es) Agentes antihelminticos y su uso.